公开(公告)号：EP3292152A1

公开(公告)日：2018-03-14

申请号：EP16723616.5

申请日：2016-05-06

申请人： Agenus Inc. ,  Ludwig Institute for Cancer Research Ltd ,  Memorial Sloan Kettering Cancer Center

发明人： VAN DIJK, Marc ,  BREOUS-NYSTROM, Ekaterina ,  SEIBERT, Volker ,  RITTER, Gerd ,  SCHAER, David ,  HIRSCHHORN-CYMERMAN, Daniel ,  MERGHOUB, Taha ,  TANG, Hao ,  SAVITSKY, David A. ,  WAIGHT, Jeremy ,  WILSON, Nicholas S.

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/524 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  G01N33/6863 ,  G01N2333/70578

摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.